Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interleukin-2 and Bevacizumab in Progressive Metastatic Renal Cell Carcinoma
NCT00440973Phase 2Terminated
- Sponsor
- Houston Methodist Research Institute
- Start
- Oct 2006
- Primary completion
- Oct 2007
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in renal cell carcinoma (RCC), sponsored by Houston Methodist Research Institute. Started Oct 2006; status: terminated.
02
Drugs
bevacizumab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00440973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00440973.